Privacy voorkeur

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


ASCO GU 2018: Renal Cell Carcinoma News Program

This year the ASCO Genitourinary Cancers Symposium took place in San Francisco from February 8th - 10th. In this Renal Cell Carcinoma News Program, we focus on the highlights for RCC at this congress.

Moderator Catherine Hood and a panel of international experts discuss the following topics:

  • Adjuvant systemic therapy
  • Cabozantinib in the first line treatment of metastatic RCC
  • The NIVOREN trial that investigates nivolumab in a ‘real world setting’
  • Combination treatments with VEGF and PD1/PD-L1 inhibition
  • Advances in treatment for papillary RCC

Speakers:

  • Prof. Joaquim Bellmunt, MD, medical oncologist, Dana-Farber/Brigham and Women's Cancer Center, Boston
  • Daniel George, MD, medical oncologist, Duke Cancer Center, Durham
  • Jeanny Aragon-Ching, MD, medical oncologist, Inova Fairfax hospital, Fairfax
  • Sumanta Pal, MD, medical oncologist, City of Hope Comprehensive Cancer Center, Duarte

Moderator: Catherine Hood

  • This program is editorially independent and is financially made possible by

Related items

Congress news

ASCO GU 2018: Progression after IO combination regimens mRCC

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined the clinical outcome of patients with metastatic renal cell carcinoma progressing on frontline immune-oncology based combination regimens.

Congress news

ASCO GU 2018: Oligoprogressive mRCC

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined what the impact was of switching systemic treatment after radiosurgery for oligoprogressive, metastatic renal cell carcinoma.

Congress news

​ASCO GU 2017: RT versus surgery in Gleason 9-10 Pca

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Amar Kishan Poster: A7 - Radiotherapy versus radical prostatectomy for Gleason score 9-10 prostate adenocarcinoma: A multi-institutional comparative analysis of 1001 patients treated in the modern era

Congress news

ASCO GU 2017: RCC news

On February 16-18, the 2017 Genitourinary Cancers Symposium took place in Orlando, Florida. The final congress day was dedicated to renal cell carcinoma. A panel of American experts will bring you the day’s highlights, which include: circulating tumor DNA frontline systemic therapy (CABOSUN, IMmotion) TKI+immunotherapy active surveillance in localized and advanced disease imaging and biomarkers for the diagnosis and monitoring of RCC cryoablation adjuvant treatment for localized tumors (ASSURE, S-TRAC) hereditary renal cancer Speakers: Prof. Eric Jonasch MD, medical oncologist, University of Texas MD Anderson cancer center, Houston TX Sumanta Pal MD, medical oncologist, City of Hope, Duarte CA Prof. Mohamad Allaf MD, urologic oncologist, John Hopkins School of Medicine, Baltimore MD Moderator: Catherine Hood PhD The news program includes an interview with prof. Thomas Powles (Barts and the London School of Medicine, UK) on the results of the IMmotion trial and his expectations for the future of atezolizumab in RCC.

Congress news

Oncology News Program at Genitourinary Cancers Symposium 2015

The 2015 Genitourinary Cancers Symposium was held in Orlando from February 26th to 28th. In a multidisciplinary Oncology News Program Dutch and Belgian experts will discuss new important data, presented at this congress. In the first part of this Oncology News Program Dr. Thierry Gil, Prof. Jeroen van Moorselaar and Dr. Fons van den Bergh talk about the role of Androgen Deprivation Therapy in early and intermediate risk prostate cancer, dose escalation in Radiotherapy, Stereotactic Body Radiotherapy and possible predictive markers like Slco2B1 and androgen receptor splice variant 7. The second part covers the following topics on prostate cancer: Active Surveillance in early stage prostate cancer, Brachytherapy versus External Beam Radiation Therapy, active immunotherapy and check point inhibitors and one of the highlights of this congress, the GETUG-15 trial. These data are discussed by Prof. Winald Gerritsen, Prof. Gert De Meerleer and Prof. Thierry Roumeguère. The panel for the last part of this Oncology News Program consists of Prof. Gerritsen, Prof. van Moorselaar and Prof. Roumeguère. The experts discuss important new data on GU-non prostate cancer: organ sparing versus radical cystectomy, (neo)adjuvant chemotherapy in bladder cancer, the role of profiling urothelial cancer, anti-PDL1 and Pazopanib in combination with Paclitaxel in refractory urothelial cancer. Presented by dr. Ayan Panja.

Congress news

ASCO GU 2017: Discussion program on prostate and bladder cancer

On February 16-18, the 2017 Genitourinary Cancers Symposium took place in Orlando, Florida. An international multidisciplinary panel discussed a selection of topics and new data on prostate and bladder cancer. During a live connection, questions were submitted by participants of the ASCO Direct GU Virtual meetings in 7 different countries (Austria, Belgium, Brazil, Germany, Netherlands, United Arabic Emirates and Switzerland) Topics: Active surveillance in localized prostate cancer Impact of ProtecT trial results Value of imaging, genomics, and genetics for active surveillance High-risk prostate cancer, definition and therapeutic controversies Value of chemoradiation for bladder cancer Molecular predictors and response to neoadjuvant chemotherapy in bladder cancer Speakers: Prof. Bertrand Tombal MD PhD, urologist, Université catholique de Louvain, Cliniques universitaires Saint-Luc, Brussels, Belgium Prof. Robert Bristow MD PhD, radiation oncologist, Princess Margaret Hospital, Toronto, Canada Prof. Thomas Bauernhofer MD, medical oncologist, University Clinic for Internal Medicine Karl-Franzens University, Graz, Austria Neil Shore MD, urologist, Atlantic Urology Clinic, Myrtle Beach, USA Moderator: Catherine Hood PhD  

Congress news

ASCO GU 2017: Testicular cancer debate summary

On February 16-18, the 2017 Genitourinary Cancers Symposium took place in Orlando, Florida. A debate was held on February 18 about marker half-life decline as a predictor of response in testicular cancer. Prof. George Bosl from the Memorial Sloan Kettering Cancer Center reflects on the key points from the debate: Usage of marker half-life decline in clinical practice Marker surge after surgery and effects on measurement Accuracy of marker decline as a predictor for response Marker-free patients Future directions to address controversies